What's New
Front Page
Guest Feature: My Ohana – Reflecting on The Close Bonds We Build on the FTD Journey
FTD symptoms and the stigma attached can make navigating the disease an isolating experience for people diagnosed,…
Schizophrenia Drug Reduces Tau Protein Aggregation in Cell and Mouse Models, Study Finds
Amisulpride, an antipsychotic drug, is capable of reducing aggregation of the tau protein in cell and mouse…
Advancing Hope: AFTD’s Director of Research Engagement Attends Cure VCP Conference
Shana Dodge, PhD, AFTD’s Director of Research Engagement, spoke at the 2023 Cure VCP Connections Conference, held…
Guest Feature: That Picture, That Movie, That Song – Connecting with My Dad Beyond FTD
FTD can distort one’s personality and behavior in unpredictable and upsetting ways, and it can be hard…
AFTD Webinar: Genetic FTD — To Test or Not to Test
The decision to learn one’s own genetic risk for developing FTD is highly personal. An individual’s test…
AFTD and Denali Therapeutics Discuss Takeda Pharmaceuticals Partnership to Develop FTD-Focused Therapeutic
Recently, members of the Denali Therapeutics team provided insights into their work and partnership with Takeda to…
